Medicine put to the test

The independent Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG) examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

Secukinumab in children with plaque psoriasis: study unsuitable for benefit assessment

2020-12-03 The comparator group was not treated appropriately. Firstly, therapy in this group remained unchanged despite non-response, and secondly, it was continued for longer than approved.

read more Link to \Secukinumab in children with plaque psoriasis: study unsuitable for benefit assessment\""

Autologous chondrocyte implantation in the knee: M-ACI has comparable benefit to therapy alternatives

2020-11-20 Only matrix-induced ACI (M-ACI) shows a benefit that is at least comparable to that of therapy alternatives. This was not shown for other ACI procedures.

read more Link to \Autologous chondrocyte implantation in the knee: M-ACI has comparable benefit to therapy alternatives\""

Trifarotene in moderate acne: no study data for the assessment of the added benefit

2020-11-16 Although acne affects many people and there are treatment alternatives, the new drug was only compared with placebo in the approval studies.

read more Link to \Trifarotene in moderate acne: no study data for the assessment of the added benefit\""

Low-dose CT for lung cancer screening: benefit outweighs potential harm

2020-11-16 An earlier initial diagnosis can reduce lung cancer mortality in heavy (ex-)smokers. The benefit outweighs the risk of harm from misdiagnosis or overdiagnosis.

read more Link to \Low-dose CT for lung cancer screening: benefit outweighs potential harm\""

Fostamatinib in chronic immune thrombocytopenia: no comparison – added benefit not proven

2020-10-01 The manufacturer conducted no direct or indirect comparison of its drug with an appropriate comparator therapy (eltrombopag or romiplostim).

read more Link to \Fostamatinib in chronic immune thrombocytopenia: no comparison – added benefit not proven\""

Pancreatic surgery: lower mortality with larger case volumes

2020-09-28 The survival probabilities are higher in hospitals where complex pancreatic surgery is performed more frequently.

read more Link to \Pancreatic surgery: lower mortality with larger case volumes\""

Talazoparib in breast cancer: hint of considerable added benefit

2020-09-01 Advantages in health-related quality of life, symptoms and side effects outweigh the few disadvantages. Data for the time after progression are missing, however.

read more Link to \Talazoparib in breast cancer: hint of considerable added benefit\""

Castration-resistant prostate cancer at high risk of metastasis: enzalutamide has added benefit

2020-08-17 For the first time, new data from the PROSPER study show an advantage in overall survival that outweighs the disadvantages in some side effects.

read more Link to \Castration-resistant prostate cancer at high risk of metastasis: enzalutamide has added benefit\""

Darolutamide in prostate cancer: indication of considerable added benefit

2020-08-03 The advantages in the outcome categories of mortality, morbidity and health-related quality of life are not accompanied by disadvantages.

read more Link to \Darolutamide in prostate cancer: indication of considerable added benefit\""

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

There are no actual comments.


Calls for tenders advertised

Calls for tenders advertised


Deadline Public tenders  
09.12.2020 12:00 Uhr [V20-05] Guideline synopsis for updating the DMP “Heart failure” 
search for:
eine vertragsärztlich tätige Hausärztin (allgemeinmedizinisch oder internistisch) / ein vertragsärztlich tätiger Hausarzt (allgemeinmedizinisch oder internistisch), die/der die in der Leistungsbeschreibung aufgeführten Leistungen erbringt.To public tender
eine vertragsärztlich tätige Fachärztin für Kardiologie / ein vertragsärztlicher tätiger Facharzt für Kardiologie, die/der die in der Leistungsbeschreibung aufgeführten Leistungen erbringt.To public tender

Easily understandable information for patients and the general community

Ravulizumab (Ultomiris) for the treatment of atypical hemolytic uremic syndrome

Ravulizumab (trade name: Ultomiris) has been approved in Germany since June 2020 for the treatment of atypical hemolytic uremic syndrome (aHUS) in people who weigh at least 10 kilograms.   read more (Link to \Ravulizumab (Ultomiris) for the treatment of atypical hemolytic uremic syndrome\"" ‚Äì opens in a new window)


Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close